Aurobindo Pharma Limited (BOM:524804)
India · Delayed Price · Currency is INR 1,432.40
+1.50 (0.10%)
At close: Jun 1, 2026
Aurobindo Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 333,847 | 317,237 | 290,019 | 248,554 | 234,555 |
Other Revenue | 2,683 | - | - | - | - |
| 336,531 | 317,237 | 290,019 | 248,554 | 234,555 | |
Revenue Growth (YoY) | 6.08% | 9.38% | 16.68% | 5.97% | -5.33% |
Cost of Revenue | 134,884 | 134,839 | 129,857 | 116,417 | 104,499 |
Gross Profit | 201,647 | 182,399 | 160,162 | 132,137 | 130,056 |
Selling, General & Admin | 51,902 | 45,470 | 40,434 | 36,560 | 35,751 |
Other Operating Expenses | 81,188 | 70,693 | 60,894 | 58,083 | 49,976 |
Operating Expenses | 150,871 | 132,074 | 116,247 | 107,018 | 96,992 |
Operating Income | 50,776 | 50,324 | 43,915 | 25,119 | 33,064 |
Interest Expense | -3,840 | -4,404 | -2,681 | -1,290 | -368.4 |
Interest & Investment Income | - | 3,564 | 2,883 | 1,485 | 349.7 |
Earnings From Equity Investments | 15.2 | -316.9 | -171.6 | -116.7 | -312.5 |
Currency Exchange Gain (Loss) | -100.7 | -226.5 | 387.8 | - | 699.6 |
Other Non Operating Income (Expenses) | 4,921 | 1,962 | 1,672 | 974.6 | 1,028 |
EBT Excluding Unusual Items | 51,772 | 50,903 | 46,006 | 26,173 | 34,461 |
Merger & Restructuring Charges | - | - | -986.6 | - | - |
Impairment of Goodwill | - | -96.2 | -27.4 | -70.3 | - |
Gain (Loss) on Sale of Investments | - | 335.3 | 1 | - | 290.8 |
Gain (Loss) on Sale of Assets | - | - | 234.9 | 132.3 | -400.2 |
Asset Writedown | - | -600.2 | -2,834 | -239.6 | -1,922 |
Other Unusual Items | -653.3 | 121.3 | 1,407 | 130.1 | 1,298 |
Pretax Income | 51,119 | 50,663 | 43,800 | 26,125 | 33,727 |
Income Tax Expense | 16,089 | 15,827 | 12,110 | 6,849 | 7,256 |
Earnings From Continuing Operations | 35,030 | 34,836 | 31,690 | 19,277 | 26,471 |
Minority Interest in Earnings | 17.7 | 23.1 | 40 | -1.5 | 10.4 |
Net Income | 35,048 | 34,859 | 31,730 | 19,275 | 26,482 |
Net Income to Common | 35,048 | 34,859 | 31,730 | 19,275 | 26,482 |
Net Income Growth | 0.54% | 9.86% | 64.62% | -27.21% | -50.36% |
Shares Outstanding (Basic) | 581 | 583 | 586 | 586 | 586 |
Shares Outstanding (Diluted) | 581 | 583 | 586 | 586 | 586 |
Shares Change (YoY) | -0.35% | -0.52% | - | - | - |
EPS (Basic) | 60.34 | 59.81 | 54.15 | 32.90 | 45.20 |
EPS (Diluted) | 60.34 | 59.81 | 54.15 | 32.90 | 45.19 |
EPS Growth | 0.89% | 10.44% | 64.62% | -27.21% | -50.37% |
Free Cash Flow | 28,406 | 19,568 | -3,458 | -170.5 | 29,636 |
Free Cash Flow Per Share | 48.91 | 33.57 | -5.90 | -0.29 | 50.58 |
Dividend Per Share | - | - | 4.500 | 3.000 | 9.000 |
Dividend Growth | - | - | 50.00% | -66.67% | 125.00% |
Gross Margin | 59.92% | 57.50% | 55.23% | 53.16% | 55.45% |
Operating Margin | 15.09% | 15.86% | 15.14% | 10.11% | 14.10% |
Profit Margin | 10.41% | 10.99% | 10.94% | 7.75% | 11.29% |
Free Cash Flow Margin | 8.44% | 6.17% | -1.19% | -0.07% | 12.63% |
EBITDA | 68,558 | 64,817 | 57,641 | 36,344 | 43,114 |
EBITDA Margin | 20.37% | 20.43% | 19.88% | 14.62% | 18.38% |
D&A For EBITDA | 17,782 | 14,492 | 13,726 | 11,225 | 10,050 |
EBIT | 50,776 | 50,324 | 43,915 | 25,119 | 33,064 |
EBIT Margin | 15.09% | 15.86% | 15.14% | 10.11% | 14.10% |
Effective Tax Rate | 31.47% | 31.24% | 27.65% | 26.21% | 21.52% |
Revenue as Reported | 341,452 | 323,456 | 295,593 | 251,460 | 237,758 |